Literature DB >> 24258576

Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1.

Faustine Ferrari1, Alice Masurel2, Laurence Olivier-Faivre3, Pierre Vabres4.   

Abstract

IMPORTANCE: The diagnosis of neurofibromatosis type 1 (NF1) is based on 7 clinical criteria. However, they are of limited value before the age of 2 years. Juvenile xanthogranuloma (JXG) and nevus anemicus (NA) are commonly observed in children with NF1 and may be useful diagnostic clues.
OBJECTIVES: To evaluate the frequency of JXG and NA, to describe their clinical features, and to determine their diagnostic value in patients with NF1. DESIGN, SETTING, AND PARTICIPANTS: Retrospective medical record review of outpatients seen between January 1, 2005, and December 31, 2011. University hospital dermatology department affiliated with the French NF1 referral center network. Patients with NF1 diagnosed by at least 2 National Institutes of Health criteria and examined at our department. MAIN OUTCOMES AND MEASURES: Percentage of patients with NF1 who had JXG or NA categorized into 4 age groups.
RESULTS: Among 72 patients with NF1 (median age, 15.4 years), 23 had JXG (10%) or NA (25%). Both lesions were more frequent (55%) in those younger than 2 years (JXG, 30%; NA, 35%). Most JXG lesions were multiple and resolved spontaneously. Cephalic and genital involvement was frequent. No patient with JXG developed chronic myelomonocytic leukemia. Nevus anemicus was present on the neck and upper chest in 72% of cases. Among 10 patients (14%) who had only 1 diagnostic criterion at first visit, including 9 younger than 2 years, JXG or NA was present in 8 (80%). CONCLUSIONS AND RELEVANCE: We found a high frequency of JXG and NA in patients with NF1, especially in children younger than 2 years with fewer than 2 diagnostic criteria. Hence, JXG and NA appear helpful in improving early diagnosis of NF1 in young children and infants.

Entities:  

Mesh:

Year:  2014        PMID: 24258576     DOI: 10.1001/jamadermatol.2013.6434

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  7 in total

1.  Juvenile xanthogranuloma in Noonan syndrome.

Authors:  Marwan M Ali; Amy E Gilliam; Beth S Ruben; William E Tidyman; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2021-05-25       Impact factor: 2.578

2.  Evaluation of clinical findings and neurofibromatosis type 1 bright objects on brain magnetic resonance images of 60 Turkish patients with NF1 gene variants.

Authors:  Filiz Hazan; Semra Gürsoy; Aycan Unalp; Unsal Yılmaz; Bengü Demirağ; Sultan Aydin Köker; Berk Ozyılmaz; Kadri Murat Erdogan; Önder Kalenderer; Serkan Erkuş; Müge Gürçınar; Ajlan Tükün
Journal:  Neurol Sci       Date:  2021-01-14       Impact factor: 3.830

Review 3.  Legius syndrome: case report and review of literature.

Authors:  Elisa Benelli; Irene Bruno; Chiara Belcaro; Alessandro Ventura; Irene Berti
Journal:  Ital J Pediatr       Date:  2015-02-08       Impact factor: 2.638

4.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

5.  Neurofibromatosis type I: points to be considered by general pediatricians.

Authors:  Eungu Kang; Hee Mang Yoon; Beom Hee Lee
Journal:  Clin Exp Pediatr       Date:  2020-07-15

6.  Type I Neurofibromatosis: Case Report and Review of the Literature Focused on Oral and Cutaneous Lesions.

Authors:  Samanta Buchholzer; Raùl Verdeja; Tommaso Lombardi
Journal:  Dermatopathology (Basel)       Date:  2021-01-07

7.  Juvenile xanthogranuloma as a new type of skin lesions in tuberous sclerosis complex.

Authors:  Qian Lu; Xiu-Yu Shi; Yang-Yang Wang; Meng-Na Zhang; Wen-Ze Wang; Jing Wang; Qiu-Hong Wang; Hui-Min Chen; Li-Ping Zou
Journal:  Orphanet J Rare Dis       Date:  2020-06-12       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.